

Paola Secchiero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9145008/publications.pdf>

Version: 2024-02-01

277
papers

11,378
citations

34016

52
h-index

40881

93
g-index

284
all docs

284
docs citations

284
times ranked

13802
citing authors

#	ARTICLE	IF	CITATIONS
1	Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. <i>Blood</i> , 2004, 104, 2418-2424.	0.6	422
2	Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. <i>Nature Medicine</i> , 1997, 3, 1394-1397.	15.2	411
3	Detection of Human Herpesvirus 6 in Plasma of Children with Primary Infection and Immunosuppressed Patients by Polymerase Chain Reaction. <i>Journal of Infectious Diseases</i> , 1995, 171, 273-280.	1.9	295
4	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 7634-7639.	3.3	295
5	COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3474.	1.8	290
6	TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways. <i>Circulation</i> , 2003, 107, 2250-2256.	1.6	283
7	CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 3872-3876.	3.3	229
8	MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 133.	6.9	213
9	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. <i>Blood</i> , 2010, 116, 945-952.	0.6	200
10	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2006, 107, 4122-4129.	0.6	156
11	Recent Advances in the Therapeutic Perspectives of Nutlin-3. <i>Current Pharmaceutical Design</i> , 2011, 17, 569-577.	0.9	150
12	Systemic Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E-Null Diabetic Mice. <i>Circulation</i> , 2006, 114, 1522-1530.	1.6	147
13	An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction. <i>American Journal of Pathology</i> , 2006, 169, 2236-2244.	1.9	129
14	TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. <i>Blood</i> , 2000, 95, 3716-24.	0.6	129
15	Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. <i>PLoS ONE</i> , 2010, 5, e11140.	1.1	128
16	Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. <i>Circulation Research</i> , 2007, 100, 61-69.	2.0	124
17	TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. <i>Cellular and Molecular Life Sciences</i> , 2004, 61, 1965-1974.	2.4	123
18	Human Herpesvirus 6: A Survey of Presence and Variant Distribution in Normal Peripheral Lymphocytes and Lymphoproliferative Disorders. <i>Journal of Infectious Diseases</i> , 1994, 170, 211-215.	1.9	121

#	ARTICLE	IF	CITATIONS
19	Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. <i>Blood</i> , 2007, 110, 536-543.	0.6	121
20	The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. <i>Cytokine and Growth Factor Reviews</i> , 2006, 17, 245-257.	3.2	120
21	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sequentially Upregulates Nitric Oxide and Prostanoid Production in Primary Human Endothelial Cells. <i>Circulation Research</i> , 2003, 92, 732-740.	2.0	119
22	TRAIL regulates normal erythroid maturation through an ERK-dependent pathway. <i>Blood</i> , 2004, 103, 517-522.	0.6	110
23	MiR-34a/c-Dependent PDGFR- β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67581.	1.1	103
24	TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF. <i>Blood</i> , 2004, 104, 2044-2050.	0.6	99
25	TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. <i>Blood</i> , 2005, 105, 3413-3419.	0.6	98
26	Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. <i>Blood</i> , 2001, 97, 2596-2603.	0.6	93
27	Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults. <i>Atherosclerosis</i> , 2011, 215, 452-458.	0.4	90
28	Evidence for a Role of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in the Anemia of Myelodysplastic Syndromes. <i>American Journal of Pathology</i> , 2005, 166, 557-563.	1.9	89
29	MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8650-8655.	3.3	86
30	The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies. <i>Current Pharmaceutical Design</i> , 2008, 14, 2100-2110.	0.9	85
31	Extracellular HIV-1 tat protein up-regulates the expression of surface CXCR4 chemokine receptor 4 in resting CD4+ T cells. <i>Journal of Immunology</i> , 1999, 162, 2427-31.	0.4	85
32	Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. <i>Blood</i> , 2002, 100, 2421-2429.	0.6	83
33	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. <i>Blood</i> , 2009, 113, 4300-4308.	0.6	83
34	Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction. <i>PLoS ONE</i> , 2009, 4, e4442.	1.1	82
35	Quantitative PCR for human herpesviruses 6 and 7. <i>Journal of Clinical Microbiology</i> , 1995, 33, 2124-2130.	1.8	80
36	Role of the extracellular domain of human herpesvirus 7 glycoprotein B in virus binding to cell surface heparan sulfate proteoglycans. <i>Journal of Virology</i> , 1997, 71, 4571-4580.	1.5	80

#	ARTICLE	IF	CITATIONS
37	HIV-1 Tat-mediated Inhibition of the Tyrosine Hydroxylase Gene Expression in Dopaminergic Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 4159-4165.	1.6	77
38	Latent BK virus infection and Kaposi's sarcoma pathogenesis. , 1996, 66, 717-722.		72
39	Role of full-length osteoprotegerin in tumor cell biology. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 841-851.	2.4	70
40	T Cell Hierarchy in the Pathogenesis of Psoriasis and Associated Cardiovascular Comorbidities. <i>Frontiers in Immunology</i> , 2018, 9, 1390.	2.2	70
41	Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. <i>Blood</i> , 2001, 98, 2220-2228.	0.6	69
42	Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells. <i>Current Drug Metabolism</i> , 2007, 8, 395-403.	0.7	69
43	miR-34a Induces the Downregulation of Both <i>E2F1</i> and <i>B-Myb</i> Oncogenes in Leukemic Cells. <i>Clinical Cancer Research</i> , 2011, 17, 2712-2724.	3.2	69
44	A set of NF- κ B-regulated microRNAs induces acquired TRAIL resistance in Lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3355-64.	3.3	68
45	Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. <i>Journal of Neurochemistry</i> , 2004, 86, 126-135.	2.1	67
46	Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. <i>Current Opinion in Hematology</i> , 2008, 15, 42-48.	1.2	66
47	Human herpesvirus 6 (variant A) in Kaposi's sarcoma. <i>Lancet, The</i> , 1993, 341, 1288-1289.	6.3	63
48	TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27 ^{Kip1} accumulation in pre-osteoclast precursors. <i>Journal of Cellular Physiology</i> , 2008, 214, 117-125.	2.0	61
49	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 210, 274-277.	0.4	61
50	Treatment With Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Alleviates the Severity of Streptozotocin-Induced Diabetes. <i>Diabetes</i> , 2010, 59, 1261-1265.	0.3	58
51	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Promotes Migration of Human Bone Marrow Multipotent Stromal Cells. <i>Stem Cells</i> , 2008, 26, 2955-2963.	1.4	56
52	Evidence for a Proangiogenic Activity of TNF-Related Apoptosis-Inducing Ligand. <i>Neoplasia</i> , 2004, 6, 364-373.	2.3	55
53	Biological and Molecular Characteristics of Human Herpesvirus 7: In Vitro Growth Optimization and Development of a Syncytia Inhibition Test. <i>Virology</i> , 1994, 202, 506-512.	1.1	54
54	Actively targeted nanocarriers for drug delivery to cancer cells. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 481-496.	2.4	52

#	ARTICLE	IF	CITATIONS
55	Presence and physical state of HPV DNA in prostate and urinary-tract tissues. <i>International Journal of Cancer</i> , 1992, 52, 359-365.	2.3	51
56	Osteoprotegerin promotes vascular fibrosis via a TGF- β 1 autocrine loop. <i>Atherosclerosis</i> , 2011, 218, 61-68.	0.4	51
57	HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts. <i>Scientific Reports</i> , 2018, 8, 17665.	1.6	50
58	Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway. <i>Clinical Cancer Research</i> , 2011, 17, 762-770.	3.2	48
59	Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. <i>Molecular and Cellular Endocrinology</i> , 2014, 394, 13-20.	1.6	48
60	Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis. <i>Scientific Reports</i> , 2019, 9, 10870.	1.6	48
61	Proper design of silica nanoparticles combines high brightness, lack of cytotoxicity and efficient cell endocytosis. <i>Nanoscale</i> , 2013, 5, 7897.	2.8	47
62	Identification of human telomeric repeat motifs at the genome termini of human herpesvirus 7: structural analysis and heterogeneity. <i>Journal of Virology</i> , 1995, 69, 8041-8045.	1.5	47
63	Human Immunodeficiency Virus Type 1 Nef Protein Sensitizes CD4+ T Lymphoid Cells to Apoptosis via Functional Upregulation of the CD95/CD95 Ligand Pathway. <i>Blood</i> , 1999, 93, 1000-1010.	0.6	45
64	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. <i>Haematologica</i> , 2012, 97, 1722-1730.	1.7	44
65	TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation. <i>Clinical Science</i> , 2012, 123, 547-555.	1.8	44
66	Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1837-1849.	2.4	44
67	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. <i>Cancers</i> , 2020, 12, 2126.	1.7	44
68	TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies. <i>Current Pharmaceutical Design</i> , 2004, 10, 3673-3681.	0.9	43
69	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. <i>American Journal of Pathology</i> , 2005, 167, 1599-1607.	1.9	43
70	The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles. <i>Journal of Virology</i> , 1997, 71, 5758-5763.	1.5	42
71	Endothelial Cells Obtained from Patients Affected by Chronic Venous Disease Exhibit a Pro-Inflammatory Phenotype. <i>PLoS ONE</i> , 2012, 7, e39543.	1.1	42
72	The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts. <i>Neoplasia</i> , 2007, 9, 853-861.	2.3	41

#	ARTICLE	IF	CITATIONS
73	Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. PLoS ONE, 2018, 13, e0193867.	1.1	40
74	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). Blood, 2000, 96, 126-131.	0.6	39
75	Cell-Based Therapies for Diabetic Complications. Experimental Diabetes Research, 2012, 2012, 1-10.	3.8	39
76	Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis). Circulation Journal, 2009, 73, 1973-1982.	0.7	38
77	Human Herpesvirus 7 induces CD4(+) T-cell death by two distinct mechanisms: necrotic lysis in productively infected cells and apoptosis in uninfected or nonproductively infected cells. Blood, 1997, 90, 4502-12.	0.6	38
78	Human immunodeficiency virus type 1 Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway. Blood, 1999, 93, 1000-10.	0.6	38
79	HIV-1 Tat protein downregulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway. FASEB Journal, 2001, 15, 483-491.	0.2	37
80	Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoïd cells. Journal of Immunology, 1999, 163, 3169-75.	0.4	37
81	Stromal derived factor-1 alpha (SDF-1 alpha) induces CD4+ T cell apoptosis via the functional up-regulation of the Fas (CD95)/Fas ligand (CD95L) pathway. Journal of Leukocyte Biology, 2001, 69, 263-70.	1.5	37
82	IFN- γ 2b Reduces IL-2 Production and IL-2 Receptor Function in Primary CD4+T Cells. Journal of Immunology, 2000, 164, 2296-2302.	0.4	36
83	C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1-Dependent Pathway. Clinical Cancer Research, 2013, 19, 1949-1959.	3.2	36
84	Clinical perspectives of TRAIL: insights into central nervous system disorders. Cellular and Molecular Life Sciences, 2016, 73, 2017-2027.	2.4	36
85	Human herpesvirus 6 and Epstein-Barr virus in Hodgkin's disease: a controlled study by polymerase chain reaction and in situ hybridization. American Journal of Pathology, 1996, 149, 1501-10.	1.9	36
86	Interference between human herpesvirus 7 and HIV-1 in mononuclear phagocytes. Journal of Immunology, 1996, 156, 2004-8.	0.4	36
87	Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation. Journal of Cellular Physiology, 2006, 206, 647-654.	2.0	35
88	TRAIL Modulates the Immune System and Protects against the Development of Diabetes. Journal of Immunology Research, 2015, 2015, 1-12.	0.9	35
89	Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Molecular and Cellular Endocrinology, 2011, 331, 136-142.	1.6	34
90	Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity. International Journal of Biochemistry and Cell Biology, 2016, 81, 364-374.	1.2	34

#	ARTICLE	IF	CITATIONS
91	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 158-164.	2.0	33
92	TRAIL and osteoprotegerin: a role in endothelial physiopathology?. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 135.	3.0	33
93	NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells. <i>The Anatomical Record</i> , 2002, 266, 87-92.	2.3	32
94	Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+ T cells. <i>Blood</i> , 2001, 98, 2474-2481.	0.6	31
95	State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2012, 7, 207-217.	0.8	31
96	TRAIL shows potential cardioprotective activity. <i>Investigational New Drugs</i> , 2012, 30, 1257-1260.	1.2	31
97	Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. <i>Blood</i> , 2008, 111, 1287-1294.	0.6	30
98	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 211, 333-336.	0.4	30
99	Soluble TRAIL is elevated in recurrent miscarriage and inhibits the in vitro adhesion and migration of HTR8 trophoblastic cells. <i>Human Reproduction</i> , 2012, 27, 2941-2947.	0.4	30
100	Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. <i>Clinical Cancer Research</i> , 2013, 19, 3871-3880.	3.2	30
101	TRAIL, OPC, and TWEAK in kidney disease: biomarkers or therapeutic targets?. <i>Clinical Science</i> , 2019, 133, 1145-1166.	1.8	30
102	Accumulation of catalytically active PKC- ζ into the nucleus of HL-60 cell line plays a key role in the induction of granulocytic differentiation mediated by all-transretinoic acid. <i>British Journal of Haematology</i> , 1998, 100, 541-549.	1.2	29
103	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. <i>Blood</i> , 1998, 92, 1685-1696.	0.6	29
104	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. <i>Rheumatology</i> , 2008, 48, 293-298.	0.9	29
105	In Vitro Characterization of Circulating Endothelial Progenitor Cells Isolated from Patients with Acute Coronary Syndrome. <i>PLoS ONE</i> , 2013, 8, e56377.	1.1	29
106	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. <i>Blood</i> , 1998, 92, 4521-4528.	0.6	28
107	Human herpesvirus type 7 in Hodgkin's disease. <i>British Journal of Haematology</i> , 1998, 101, 492-499.	1.2	27
108	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF- α promote the NF- κ B-dependent maturation of normal and leukemic myeloid cells. <i>Journal of Leukocyte Biology</i> , 2003, 74, 223-232.	1.5	27

#	ARTICLE	IF	CITATIONS
109	<i>MDM4 (MDMX)</i> is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 ^{wild-type} CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	1.2	27
110	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2005, 205, 246-252.	2.0	26
111	Context-dependent function of ROS in the vascular endothelium: The role of the Notch pathway and shear stress. <i>BioFactors</i> , 2017, 43, 475-485.	2.6	26
112	CCR4+ Skin-Tropic Phenotype as a Feature of Central Memory CD8+ T Cells in Healthy Subjects and Psoriasis Patients. <i>Frontiers in Immunology</i> , 2020, 11, 529.	2.2	26
113	Engagement of CD28 Modulates CXC Chemokine Receptor 4 Surface Expression in Both Resting and CD3-Stimulated CD4+ T Cells. <i>Journal of Immunology</i> , 2000, 164, 4018-4024.	0.4	25
114	Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell hyperactivation and HIV type 1 replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14620-14625.	3.3	25
115	Functional expression of TRAIL and TRAIL-R2 during human megakaryocytic development. <i>Journal of Cellular Physiology</i> , 2005, 204, 975-982.	2.0	25
116	The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement. <i>Acta Diabetologica</i> , 2014, 51, 239-246.	1.2	25
117	Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. <i>Oncotarget</i> , 2016, 7, 18965-18977.	0.8	25
118	<i>In Vitro</i> Susceptibility of <i>Macaca nemestrina</i> to Human Herpesvirus 6: A Potential Animal Model of Coinfection with Primate Immunodeficiency Viruses. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 181-187.	0.5	24
119	Identification and Analysis of a Novel Heparin-Binding Glycoprotein Encoded by Human Herpesvirus 7. <i>Journal of Virology</i> , 2000, 74, 4530-4540.	1.5	24
120	Patients affected by metabolic syndrome show decreased levels of circulating platelet derived growth factor (PDGF)-BB. <i>Clinical Nutrition</i> , 2013, 32, 259-264.	2.3	24
121	Endothelial PDGF-BB produced <i>ex vivo</i> correlates with relevant hemodynamic parameters in patients affected by chronic venous disease. <i>Cytokine</i> , 2013, 63, 92-96.	1.4	24
122	Modulation of Circulating Cytokine-Chemokine Profile in Patients Affected by Chronic Venous Insufficiency Undergoing Surgical Hemodynamic Correction. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	24
123	Sex/Gender-Specific Imbalance in CVD: Could Physical Activity Help to Improve Clinical Outcome Targeting CVD Molecular Mechanisms in Women?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1477.	1.8	24
124	Differential effects of stromal derived factor-1? (SDF-1?) on early and late stages of human megakaryocytic development. <i>The Anatomical Record</i> , 2000, 260, 141-147.	2.3	23
125	The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2010, 16, 1824-1833.	3.2	23
126	Multimodal near-infrared-emitting Plus Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 4865-4874.	3.3	23

#	ARTICLE	IF	CITATIONS
127	Upregulation of the alternative splicing factor NOVA2 in colorectal cancer vasculature. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6049-6056.	1.0	23
128	Coagulation Factor XII Levels and Intrinsic Thrombin Generation in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2018, 9, 245.	1.1	23
129	MDM2 Antagonist Nutlin-3 Suppresses the Proliferation and Differentiation of Human Pre-Osteoclasts Through a p53-Dependent Pathway. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1621-1630.	3.1	22
130	Ultrastructure of internal jugular vein defective valves. <i>Phlebology</i> , 2015, 30, 644-647.	0.6	22
131	Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 147-156.	2.9	22
132	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. <i>Oncogene</i> , 2017, 36, 6617-6626.	2.6	22
133	Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. <i>Oncotarget</i> , 2014, 5, 4347-4360.	0.8	22
134	Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol. <i>PLoS ONE</i> , 2013, 8, e58225.	1.1	21
135	Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 70623-70638.	0.8	21
136	The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40. <i>Acta Diabetologica</i> , 2013, 50, 899-906.	1.2	20
137	Serum From Advanced Heart Failure Patients Promotes Angiogenic Sprouting and Affects the Notch Pathway in Human Endothelial Cells. <i>Journal of Cellular Physiology</i> , 2016, 231, 2700-2710.	2.0	20
138	SARS-CoV-2 nucleocapsid protein and ultrastructural modifications in small bowel of a 4-week-negative COVID-19 patient. <i>Clinical Microbiology and Infection</i> , 2021, 27, 936-937.	2.8	20
139	Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels. <i>Journal of Immunology</i> , 1997, 159, 3412-23.	0.4	20
140	TRAIL pathway components and their putative role in granulosa cell apoptosis in the human ovary. <i>Differentiation</i> , 2009, 77, 369-376.	1.0	19
141	TNF- α modulates the migratory response of mesenchymal stem cells to TRAIL. <i>Cellular and Molecular Life Sciences</i> , 2010, 67, 1307-1314.	2.4	19
142	The β -secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells. <i>Oncotarget</i> , 2017, 8, 59235-59245.	0.8	19
143	Characterization of Human Herpesvirus 6 Strains Isolated from Patients with Exanthem Subitum with or without Cutaneous Rash. <i>Journal of Infectious Diseases</i> , 1992, 166, 689-689.	1.9	18
144	Cloning, restriction endonuclease mapping and partial sequence analysis of the genome of human herpesvirus 7 strain JI. <i>Journal of General Virology</i> , 1996, 77, 1901-1912.	1.3	18

#	ARTICLE	IF	CITATIONS
145	Inhibitory Effect of Natural Anti-Inflammatory Compounds on Cytokines Released by Chronic Venous Disease Patient-Derived Endothelial Cells. <i>Mediators of Inflammation</i> , 2013, 2013, 1-13.	1.4	18
146	Multiple dye-doped NIR-emitting silica nanoparticles for both flow cytometry and in vivo imaging. <i>RSC Advances</i> , 2014, 4, 18278-18285.	1.7	18
147	Oscillatory flow suppression improves inflammation in chronic venous disease. <i>Journal of Surgical Research</i> , 2016, 205, 238-245.	0.8	18
148	The effectiveness of Robot-Assisted Gait Training versus conventional therapy on mobility in severely disabled progressive Multiple sclerosis patients (RAGTIME): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 88.	0.7	18
149	Nutlin-3 Downregulates the Expression of the Oncogene <i>TCL1</i> in Primary B Chronic Lymphocytic Leukemic Cells. <i>Clinical Cancer Research</i> , 2011, 17, 5649-5655.	3.2	17
150	TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse. <i>Clinical Science</i> , 2018, 132, 69-83.	1.8	16
151	Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients. <i>Frontiers in Pharmacology</i> , 2020, 11, 1156.	1.6	16
152	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR α /SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020, 10, 504.	1.3	16
153	Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9449.	1.8	16
154	The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. <i>Oncotarget</i> , 2015, 6, 2385-2396.	0.8	16
155	Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model. <i>PLoS ONE</i> , 2014, 9, e115387.	1.1	15
156	Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. <i>Journal of Leukocyte Biology</i> , 2008, 83, 434-437.	1.5	14
157	Merkel-cell polyomavirus (MCPyV) is rarely associated to B-chronic lymphocytic leukemia (1 out of 50) samples and occurs late in the natural history of the disease. <i>Journal of Clinical Virology</i> , 2012, 55, 367-369.	1.6	14
158	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013, 6, 83.	6.9	14
159	Inverse Correlation Between Circulating Levels of TNF-Related Apoptosis-Inducing Ligand and 17 β -Estradiol. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E659-E664.	1.8	14
160	Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0203716.	1.1	14
161	Development of Recombinant Diagnostic Reagents Based on pp85(U14) and p86(U11) Proteins To Detect the Human Immune Response to Human Herpesvirus 7 Infection. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3980-3985.	1.8	14
162	Autoinflammatory Diseases and Cytokine Storms – Imbalances of Innate and Adaptive Immunity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11241.	1.8	14

#	ARTICLE	IF	CITATIONS
163	TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE(2) production in cells of the myeloid lineage. <i>Journal of Leukocyte Biology</i> , 2002, 72, 986-94.	1.5	14
164	Is vestibular papillomatosis associated with human papillomavirus?. <i>Journal of Medical Virology</i> , 1991, 35, 7-13.	2.5	13
165	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. <i>Experimental Hematology</i> , 2004, 32, 925-934.	0.2	13
166	State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies. <i>Current Medicinal Chemistry</i> , 2012, 19, 4875-4884.	1.2	13
167	Plasma levels of soluble NCAM in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2019, 396, 36-41.	0.3	13
168	The Italian law on body donation: A position paper of the Italian College of Anatomists. <i>Annals of Anatomy</i> , 2021, 238, 151761.	1.0	13
169	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. <i>Current Drug Targets</i> , 2012, 13, 1215-1221.	1.0	13
170	IFN- γ Increases Interleukin-10 Expression in Primary Activated Human CD8+T Cells. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1167-1173.	0.5	12
171	Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 2279-2286.	2.0	12
172	TRAIL administration down-modulated the acute systemic inflammatory response induced in a mouse model by muramyl dipeptide or lipopolysaccharide. <i>Cytokine</i> , 2012, 60, 43-46.	1.4	12
173	Activation of the p53 pathway induces α -smooth muscle actin expression in both myeloid leukemic cells and normal macrophages. <i>Journal of Cellular Physiology</i> , 2012, 227, 1829-1837.	2.0	12
174	In Vitro Endothelial Cell Proliferation Assay Reveals Distinct Levels of Proangiogenic Cytokines Characterizing Sera of Healthy Subjects and of Patients with Heart Failure. <i>Mediators of Inflammation</i> , 2014, 2014, 1-11.	1.4	12
175	Rehabilitation Improves Mitochondrial Energetics in Progressive Multiple Sclerosis: The Significant Role of Robot-Assisted Gait Training and of the Personalized Intensity. <i>Diagnostics</i> , 2020, 10, 834.	1.3	12
176	GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature. <i>Diagnostics</i> , 2021, 11, 604.	1.3	12
177	Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53 ^{wildtype} ; JVM-2 But Not Towards p53 ^{mutated} ; BJAB Leukemic Cells. <i>Current Medicinal Chemistry</i> , 2013, 20, 2712-2722.	1.2	12
178	TRAIL Activates a Caspase 9/7-Dependent Pathway in Caspase 8/10-Defective SK-N-SH Neuroblastoma Cells with Two Functional End Points: Induction of Apoptosis and PGE2 Release. <i>Neoplasia</i> , 2003, 5, 457-466.	2.3	11
179	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. <i>Journal of Cellular Physiology</i> , 2007, 213, 229-236.	2.0	11
180	The Puzzling Role of TRAIL in Endothelial Cell Biology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, e4; author reply e5-6.	1.1	11

#	ARTICLE	IF	CITATIONS
181	Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementary Table). <i>Current Cancer Drug Targets</i> , 2009, 9, 510-518.	0.8	11
182	Conjunctival sac fluid contains elevated levels of soluble TRAIL: Implications for the anti-tumoral surveillance of the anterior surface of the eye. <i>Journal of Cellular Physiology</i> , 2009, 218, 199-204.	2.0	11
183	Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity. <i>British Journal of Haematology</i> , 2010, 148, 957-961.	1.2	11
184	The energy balance positively regulates the levels of circulating TNF-related apoptosis inducing ligand in humans. <i>Clinical Nutrition</i> , 2012, 31, 1018-1021.	2.3	11
185	GM-CSF Exhibits Anti-Inflammatory Activity on Endothelial Cells Derived from Chronic Venous Disease Patients. <i>Mediators of Inflammation</i> , 2013, 2013, 1-9.	1.4	11
186	Selective induction of TP53/p53-inducible gene 3 (PIG3) in myeloid leukemic cells, but not in normal cells, by Nutlin-3. <i>Molecular Carcinogenesis</i> , 2014, 53, 498-504.	1.3	11
187	Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 273-280.	0.7	11
188	Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity. <i>Frontiers in Physiology</i> , 2018, 9, 1000.	1.3	11
189	Eosinophils and Purinergic Signaling in Health and Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1339.	2.2	11
190	Anticancer Activity of Aqueous Extracts from <i>Asparagus officinalis</i> L. Byproduct on Breast Cancer Cells. <i>Molecules</i> , 2021, 26, 6369.	1.7	11
191	Synthesis and Biological Investigation of Bile Acid-Paclitaxel Hybrids. <i>Molecules</i> , 2022, 27, 471.	1.7	11
192	Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). <i>Journal of Cellular Physiology</i> , 2010, 222, 357-364.	2.0	10
193	Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus. <i>Current Pharmaceutical Design</i> , 2012, 18, 5759-5765.	0.9	10
194	Human Colostrum and Breast Milk Contain High Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL). <i>Journal of Human Lactation</i> , 2013, 29, 23-25.	0.8	10
195	Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cells. <i>Nutrition</i> , 2013, 29, 332-337.	1.1	10
196	Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS). <i>Genes</i> , 2019, 10, 634.	1.0	10
197	Gene duplication, rather than epigenetic changes, drives FGF4 overexpression in KIT/PDGFR α /SDH/RAS-P WT GIST. <i>Scientific Reports</i> , 2020, 10, 19829.	1.6	10
198	Colorectal Cancer Study with Nanostructured Sensors: Tumor Marker Screening of Patient Biopsies. <i>Nanomaterials</i> , 2020, 10, 606.	1.9	10

#	ARTICLE	IF	CITATIONS
199	Stromal derived factor-1 \pm induces apoptosis in activated primary CD4+ T cells. <i>Aids</i> , 2000, 14, 748-750.	1.0	10
200	Human Herpesvirus 7 Infection Induces Profound Cell Cycle Perturbations Coupled to Disregulation of cdc2 and Cyclin B and Polyploidization of CD4+ T Cells. <i>Blood</i> , 1998, 92, 1685-1696.	0.6	10
201	Infection of CD34+ hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). <i>Blood</i> , 2000, 96, 126-131.	0.6	10
202	Infection of CD34(+) hematopoietic progenitor cells by human herpesvirus 7 (HHV-7). <i>Blood</i> , 2000, 96, 126-31.	0.6	10
203	Identification of Envelope Glycoproteins H and B Homologues of Human Herpesvirus 7. <i>Intervirolgy</i> , 1997, 40, 22-32.	1.2	9
204	Elevated levels of TRAIL in systemic lupus erythematosus are associated to the presence of anti-SSA/SSB antibodies. <i>Lupus</i> , 2007, 16, 479-482.	0.8	9
205	Selection and Characterization of a Novel Agonistic Human Recombinant Anti-Trail-R2 Minibody with Antileukemic Activity. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 73-83.	1.0	9
206	The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?. <i>Rheumatology</i> , 2010, 49, 1173-1176.	0.9	9
207	Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2010, 37, 1461-1466.	1.0	9
208	The calendar of cytokines: Seasonal variation of circulating cytokines in chronic venous insufficiency. <i>JRSM Cardiovascular Disease</i> , 2017, 6, 204800401772927.	0.4	9
209	TRAIL treatment prevents renal morphological changes and TGF- β ² -induced mesenchymal transition associated with diabetic nephropathy. <i>Clinical Science</i> , 2020, 134, 2337-2352.	1.8	9
210	The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias. <i>Oncotarget</i> , 2014, 5, 12635-12645.	0.8	9
211	Sensitization of multidrug resistant human osteosarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. <i>International Journal of Oncology</i> , 2004, 25, 1599.	1.4	8
212	Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Modulates the Expression of Genes Involved in Apoptosis and Cell Cycle in Human Osteoclasts. <i>Anatomical Record</i> , 2007, 290, 838-845.	0.8	8
213	TRAIL as Biomarker and Potential Therapeutic Tool for Cardiovascular Diseases. <i>Current Drug Targets</i> , 2012, 13, 1089-1095.	1.0	8
214	TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress. <i>Mediators of Inflammation</i> , 2018, 2018, 1-8.	1.4	8
215	The induction of megakaryocyte differentiation is accompanied by selective Ser133 phosphorylation of the transcription factor CREB in both HEL cell line and primary CD34+ cells. <i>Blood</i> , 1998, 92, 472-80.	0.6	8
216	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. <i>Leukemia</i> , 2010, 24, 480-483.	3.3	7

#	ARTICLE	IF	CITATIONS
217	The early determination of circulating TRAIL levels does not predict the development of pre-eclampsia. <i>Placenta</i> , 2012, 33, 135-136.	0.7	7
218	<sc>MCL</sc>1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor <sc>S</sc>orafenib with respect to <sc>D</sc>asatinib. <i>British Journal of Haematology</i> , 2012, 157, 510-514.	1.2	7
219	Levels of TNF-Related Apoptosis-Inducing Ligand (TRAIL) Show a Long-term Stability in the Breast Milk of Mothers of Preterm Infants. <i>Journal of Human Lactation</i> , 2013, 29, 350-353.	0.8	7
220	Soluble TRAIL is present at high concentrations in seminal plasma and promotes spermatozoa survival. <i>Reproduction</i> , 2014, 148, 191-198.	1.1	7
221	Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus. <i>Acta Diabetologica</i> , 2015, 52, 1003-1006.	1.2	7
222	Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102319.	0.9	7
223	Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to dysregulation of cdc2 and cyclin B and polyploidization of CD4(+) T cells. <i>Blood</i> , 1998, 92, 1685-96.	0.6	7
224	TRAIL, caspases and maturation of normal and leukemic myeloid precursors. <i>Leukemia and Lymphoma</i> , 2006, 47, 1459-1468.	0.6	6
225	Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 1063-1065.	1.6	6
226	Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1196-1197.	0.5	6
227	Circulating levels of frizzled-related protein (FRZB) are increased in patients with early rheumatoid arthritis and decrease in response to disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1733-1734.	0.5	6
228	Circulating TRAIL Shows a Significant Post-Partum Decline Associated to Stressful Conditions. <i>PLoS ONE</i> , 2011, 6, e27011.	1.1	6
229	Decreased levels of soluble TNF-related apoptosis-inducing ligand (TRAIL) in the conjunctival sac fluid of patients with diabetes affected by proliferative retinopathy. <i>Diabetic Medicine</i> , 2011, 28, 1277-1278.	1.2	6
230	Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells. <i>Investigational New Drugs</i> , 2012, 30, 1731-1735.	1.2	6
231	Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women. <i>Mediators of Inflammation</i> , 2017, 2017, 1-8.	1.4	6
232	Upregulation of SOCS-1 by Nutlin-3 in acute myeloid leukemia cells but not in primary normal cells. <i>Clinics</i> , 2014, 69, 68-74.	0.6	6
233	Progressive and Persistent Downregulation of Surface CXCR4 in CD4+ T Cells Infected With Human Herpesvirus 7. <i>Blood</i> , 1998, 92, 4521-4528.	0.6	6
234	Enforced expression of human bcl-2 in CD4+ T cells enhances human herpesvirus 7 replication and induction of cytopathic effects. <i>European Journal of Immunology</i> , 1998, 28, 1587-1596.	1.6	5

#	ARTICLE	IF	CITATIONS
235	Letter by Secchiero and Zauli Regarding Article, "Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in LDLr ^{-/-} Mice" Circulation, 2008, 118, e18; author reply e19.	1.6	5
236	Molecular targets for selective killing of TRAIL-resistant leukemic cells. Expert Opinion on Therapeutic Targets, 2011, 15, 931-942.	1.5	5
237	TRAIL, a New Weapon against Neointimal Hyperplasia. Cardiology, 2012, 123, 94-96.	0.6	5
238	JCV+ Patients with Inflammatory Bowel Disease show elevated plasma levels of MIG and SCF. Inflammatory Bowel Diseases, 2012, 18, 1194-1196.	0.9	5
239	Anti-leukemic activity of Dasatinib in both p53 wild-type and p53 mutated B malignant cells. Investigational New Drugs, 2012, 30, 417-422.	1.2	5
240	TNF-Related Apoptosis Inducing Ligand in Ocular Cancers and Ocular Diabetic Complications. BioMed Research International, 2015, 2015, 1-8.	0.9	5
241	MicroRNAs as New Players in the Genomic Galaxy and Disease Puzzles. Clinical and Translational Science, 2008, 1, 50-56.	1.5	4
242	Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Investigational New Drugs, 2012, 30, 803-807.	1.2	4
243	Role of vitamin D in the pathogenesis of atheromatosis. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 344-353.	1.1	4
244	MDM2 Non-Genotoxic Inhibitors as Innovative Therapeutic Approaches for the Treatment of Pediatric Malignancies. Current Medicinal Chemistry, 2013, 20, 2226-2236.	1.2	4
245	The Induction of Megakaryocyte Differentiation Is Accompanied by Selective Ser133 Phosphorylation of the Transcription Factor CREB in Both HEL Cell Line and Primary CD34+ Cells. Blood, 1998, 92, 472-480.	0.6	4
246	TRAIL/DR5 pathway promotes AKT phosphorylation, skeletal muscle differentiation, and glucose uptake. Cell Death and Disease, 2021, 12, 1089.	2.7	4
247	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2021, 11, 778461.	1.3	4
248	The engagement of CD4 surface antigen in the HEL haemopoietic cell line up-regulates the transforming growth factor- β 1 (TGF- β 1) promoter activity. British Journal of Haematology, 1997, 97, 571-578.	1.2	3
249	Role of TRAIL in osteoclastogenesis. Blood, 2008, 111, 5413-5413.	0.6	3
250	In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody. Investigational New Drugs, 2012, 30, 405-407.	1.2	3
251	Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. Investigational New Drugs, 2012, 30, 828-832.	1.2	3
252	Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors" implications for therapeutic potential. Tumor Biology, 2016, 37, 11909-11916.	0.8	3

#	ARTICLE	IF	CITATIONS
253	Novel Compliant Scaffold with Specific Design for Venous System: Results of a Porcine Model Study. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	3
254	Baseline and overtime variations of soluble adhesion molecule plasma concentrations are associated with mobility recovery after rehabilitation in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 352, 577473.	1.1	3
255	Progressive and persistent downregulation of surface CXCR4 in CD4(+) T cells infected with human herpesvirus 7. <i>Blood</i> , 1998, 92, 4521-8.	0.6	3
256	Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2009, 145, 424-426.	1.2	2
257	Unsung Hero Robert C. Gallo. <i>Science</i> , 2009, 323, 206-207.	6.0	2
258	Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1. <i>Investigational New Drugs</i> , 2013, 31, 780-786.	1.2	2
259	The circulating levels of TRAIL are extremely low after delivery but rapidly recover in both mothers and newborns. <i>Cytokine</i> , 2013, 64, 51-53.	1.4	2
260	Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	1.4	2
261	Expeditious Synthesis and Biological Characterization of Enantio-Enriched (α)-Nutlin-3. <i>ChemistrySelect</i> , 2017, 2, 8504-8508.	0.7	2
262	Association between thyroid hormones and TRAIL. <i>Clinical Biochemistry</i> , 2017, 50, 972-976.	0.8	2
263	Overcoming of Microenvironment Protection on Primary Chronic Lymphocytic Leukemia Cells after Treatment with BTK and MDM2 Pharmacological Inhibitors. <i>Current Oncology</i> , 2021, 28, 2439-2451.	0.9	2
264	Identification and Analysis of a Novel Heparin-Binding Glycoprotein Encoded by Human Herpesvirus 7. <i>Journal of Virology</i> , 2000, 74, 4530-4540.	1.5	2
265	Simultaneous determination of multiple cytokines reveals a pro-inflammatory and pro-angiogenic signature after major cardiothoracic surgery: Potential role of C-reactive protein. <i>Cytokine</i> , 2012, 60, 593-595.	1.4	1
266	The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL. <i>Investigational New Drugs</i> , 2012, 30, 810-818.	1.2	1
267	Association of Serum Tumor Necrosis Factor-Related Apoptosis Inducing Ligand with Body Fat Distribution as Assessed by Dual X-Rays Absorptiometry. <i>Mediators of Inflammation</i> , 2014, 2014, 1-6.	1.4	1
268	A novel endovenous scaffold for the treatment of chronic venous obstruction in a porcine model: Histological and ultrastructural assessment. <i>Phlebology</i> , 2019, 34, 336-346.	0.6	1
269	Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the Inflammation. <i>Biomolecules</i> , 2021, 11, 1438.	1.8	1
270	AB0419...Frequency of disease flare and study of the cd4+cd25+highcd127low/- cell populations after discontinuation of anti-tnf α therapy in patients with rheumatoid arthritis in persistent remission. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
271	The long and winding road may be getting shorter. <i>Blood</i> , 2005, 105, 4160-4160.	0.6	0
272	Potential involvement of TRAIL in Treg cell-mediated osteoclast suppression: Comment on the article by Zaiss et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 1887-1887.	6.7	0
273	TNFRSF11B (tumor necrosis factor receptor superfamily, member 11b). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	0
274	Levels of circulating TNF-related apoptosis-inducing ligand in celiac disease. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1906-1908.	0.8	0
275	Aberrant Expression of Trail in B Chronic Lymphocytic Leukemia (B-CLL) Cells.. <i>Blood</i> , 2005, 106, 4976-4976.	0.6	0
276	B-Cell Chronic Lymphocytic Leukemia Cells Exposed to the Non-Genotoxic p53 Activator Nutlin-3 Are Characterized by a Specific Gene Expression Signature.. <i>Blood</i> , 2009, 114, 4374-4374.	0.6	0
277	Merkel-Cell Polyomavirus Is Rarely Associated to B-Chronic Lymphocytic Leukemia and Occurs Late in the Natural History of the Disease. <i>Blood</i> , 2012, 120, 4578-4578.	0.6	0